BLC
AMGN icon

Blue Line Capital’s Amgen AMGN Stock Holding History

Blue Line Capital’s Portfolio AMGN Stock Details AMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.49M Sell
4,110
-1,452
-26% -$497K 1.24% 27
2026
Q1 		$1.96M Buy
5,562
+412
+8% +$147K 2.21% 14
2025
Q4 		$1.69M Buy
+5,150
New +$1.63M 1.99% 13

Other funds holding AMGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Blue Line Capital's AMGN Position: Q2 2026 in Review

Blue Line Capital reduced its Amgen (AMGN) stake by 26% in Q2 2026, selling an estimated $497K and leaving 4,110 shares worth $1.49M. The position accounts for 1.24% of the portfolio, ranked #27.

Blue Line Capital first reported a position in AMGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.96M in Q1 2026. 3,139 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Blue Line Capital held 4,110 shares of Amgen worth $1.49M as of Q2 2026.
  • Blue Line Capital sold 1,452 Amgen shares in Q2 2026, an estimated $497K.
  • Amgen made up 1.24% of Blue Line Capital's portfolio in Q2 2026, its #27 holding.
  • Blue Line Capital first reported a position in Amgen in Q4 2025 and has held it in 3 quarters since.
  • Blue Line Capital's Amgen position peaked at $1.96M in Q1 2026.
  • 3,139 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Blue Line Capital's 13F filing for Q2 2026, filed 30 Jul 2026.